Anti-CGRP Class Reduces Migraine Burden Regardless of Concomitant Therapies in US Clinical Practice
Authors: Christopher H. Gottschalk, MD, FAHS; Kristen Henn, MHS; Jennifer Robinson; Virginia R. Schobel, MSc OBJECTIVE: Assess the clinical response to anti-calcitonin gene-related peptide (CGRP) therapies across the spectrum of migraine one year after the introduction of this new class of drugs. BACKGROUND: Since 2018, three different anti-CGRP agents have been available for migraine prevention. […]
Evolving Diagnosis and Treatment of Secondary Progressive Multiple Sclerosis in the United States
Authors: Robert T. Naismith, MD; Jennifer Robinson; Virginia R. Schobel, MSc OBJECTIVE: Evaluate how US Neurologists are diagnosing secondary progressive (SP) multiple sclerosis (MS) over time. Determine how treatment choices for SPMS are evolving. BACKGROUND: In 2019, the FDA changed the prescribing information to include active SPMS for siponimod, in addition to natalizumab, ocrelizumab, cladribine, […]
Multiple Sclerosis Disease-Modifying Therapy: Recent Switch Patterns Among United States Neurologists
Authors: Patricia K. Coyle, MD; Jennifer Robinson; Virginia R. Schobel. MSc OBJECTIVE: To examine multiple sclerosis (MS) disease-modifying therapy (DMT) switch patterns by US Neurologists over the last 4 years. BACKGROUND: Cross-sectional patient-level data was collected once-yearly. It was then reviewed by an independent market intelligence agency which specializes in tracking the MS market, including […]
Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports
From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights…(read more)
Specialty Physicians Predict More Pain Ahead in the Battle Against COVID-19
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to the latest update from Spherix Global Insights EXTON, Pa., April 9, 2020 / PRNewswire / – Special Report: Multi-Specialty Impact of COVID-19 is an independent project being run by Spherix to assess the impact of […]
Roche’s Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis’ Mayzent and Ofatumumab May Threaten the Brand’s Long-Term Dominance
In the wake of the Mayzent EMA approval, neurologists expect to diagnose more patients with active secondary progressive multiple sclerosis to broaden the pool of patients eligible for the second-to-market S1P receptor modulator, according to Spherix Global Insights EXTON, Pa., April 9, 2020 ― Driven by expanded access to and uptake of disease-modifying therapies (DMTs) […]
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists’ Prelaunch Expectations that Biohaven’s Nurtec ODT Would Challenge Allergan’s Ubrelvy and Eli Lilly’s Reyvow
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on the prevention market, placing considerable stress on Amgen/Novartis’ Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Lundbeck’s Vyepti trajectories, according to Spherix Global Insights EXTON, Pa., April 2, 2020 ― Biohaven’s Nurtec (rimegepant) orally disintegrating tablet […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
Genentech’s Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis’ Mayzent and EMD Serono’s Mavenclad, While Biogen’s Vumerity Begins to Chip Away at the Company’s Own Tecfidera
Key label advantages related to cortical grey matter/thalamic volume loss reduction and superior safety compared to Novartis’ Gilenya will be fundamental for preferential uptake of Bristol Myers Squibb’s Zeposia (ozanimod), according to Spherix Global Insights EXTON, Pa., March 10, 2020 ― In the last year, the US multiple sclerosis (MS) market saw the introduction of […]
Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS
From: Multiple Sclerosis News Today By: Ana Pena, PHD. Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech’s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights’ report…(read more).
